

In the Claims

This listing of claims will replace all prior versions and listings of claims in this application.

1 (original). A method for treating idiopathic hyperhidrosis, wherein said method comprises administering to a patient a therapeutically effective amount of a 5-HT_{2C} receptor activity affecting compound.

2 (original). The method of claim 1, wherein said 5-HT_{2C} receptor activity affecting compound is selected from the group consisting of 5-HT_{2C} receptor antagonists and 5-HT_{2C} modulators.

3 (original). The method of claim 2, wherein said 5-HT_{2C} receptor antagonist is selected from the group consisting of ketanserin, ritanserin, mianserin, mclergine, cyproheptadine, fluoxetine, mirtazapine, olanzapine, and ziprasidone.

4-5 (canceled).

6 (original). The method of claim 1, wherein said 5-HT_{2C} receptor activity affecting compound is administered to the patient via a route selected from the group consisting of oral, topical, mucosal, systemic, parenteral, intravenous, intraperitoneal, subcutaneous, intramuscular, intraoral, rectal, epicutaneous, transdermal, intranasal, sublingual, buccal, intradural, intraocular, intrarespiratory, and intra nasal inhalation.

7 (original). The method of claim 1, wherein said 5-HT_{2C} receptor activity affecting compound is administered to the patient via liposome delivery systems.

8-10 (canceled).

11 (original). The method of claim 1, further comprising the step of concurrently administering a method for treating sweating.

12 (original). The method of claim 11, wherein said method for treating sweating is selected from the group consisting of iontophoresis, endoscopic thoracic sympathectomy, and botulinum toxin injection.

13 (original). A method for treating symptoms or associated conditions of idiopathic hyperhidrosis, wherein said method comprises administering to a patient a therapeutically effective amount of a 5-HT_{2C} receptor activity affecting compound.

14 (original). The method of claim 13, wherein said 5-HT_{2C} receptor activity affecting compound is selected from the group consisting of 5-HT_{2C} receptor antagonists and 5-HT_{2C} modulators.

15 (original). The method of claim 14, wherein said 5-HT_{2C} receptor antagonist is selected from the group consisting of ketanserin, ritanserin, mianserin, meclizine, cyproheptadine, fluoxetine, mirtazapine, olanzapine, and ziprasidone.

16-17 (canceled).

18 (original). The method of claim 13, wherein said 5-HT_{2C} receptor activity affecting compound is administered to the patient via a route selected from the group consisting of oral, topical, mucosal, systemic, parenteral, intravenous, intraperitoneal, subcutaneous, intramuscular, intraoral, rectal, epicutaneous, transdermal, intranasal, sublingual, buccal, intradural, intraocular, intracranial, and intra nasal inhalation forms.

19 (original). The method of claim 13, wherein said 5-HT_{2C} receptor activity affecting compound is administered to the patient via liposome delivery systems.

20-22 (canceled).

23 (original). The method of claim 13, further comprising the step of concurrently administering a method for treating sweating.

24 (original). The method of claim 23, wherein said method for treating sweating is selected from the group consisting of iontophoresis, endoscopic thoracic sympathectomy, and botulinum toxin injection.

25-31 (canceled).

32 (currently amended). A method for prophylactically preventing or minimizing perspiring associated with idiopathic hyperhidrosis, wherein said method comprises administering to a patient a therapeutically effective amount of a 5-HT_{2C} receptor activity affecting compound.

33 (original). The method of claim 32, wherein said 5-HT_{2C} receptor activity affecting compound is selected from the group consisting of 5-HT_{2C} receptor antagonists and 5-HT_{2C} modulators.

34 (original). The method of claim 33, wherein said 5-HT_{2C} receptor antagonist is selected from the group consisting of ketanserin, ritanserin, mianserin, meclizine, cyproheptadine, fluoxetine, mirtazapine, olanzapine, and ziprasidone.

35-36 (canceled).

37 (original). The method of claim 32, wherein said 5-HT_{2C} receptor activity affecting compound is administered to the patient via a route selected from the group consisting of oral, topical, mucosal, systemic, parenteral, intravenous, intraperitoneal, subcutaneous, intramuscular, intraoral, rectal, epicutaneous, transdermal, intranasal, sublingual, buccal, intradural, intraocular, intrarespiratory, and intra nasal inhalation forms.

38 (original). The method of claim 32, wherein said 5-HT_{2C} receptor activity affecting compound is administered to the patient via liposome delivery systems.

39-41 (canceled).

42 (original). The method of claim 32, further comprising the step of concurrently administering a method for treating sweating.

43 (original). The method of claim 32, wherein said method for treating sweating is selected from the group consisting of iontophoresis, endoscopic thoracic sympathectomy, and botulinum toxin injection.

44 (previously presented). The method of claim 13, wherein the associated conditions of idiopathic hyperhidrosis are selected from the group consisting of: eczematous dermatitis; contact dermatitis; miliaria; and bromhidroses.

45 (previously presented). The method of claim 6, wherein said receptor activity affecting compound is administered to the patient via injection.

46 (previously presented). The method of claim 18, wherein said receptor activity affecting compound is administered to the patient via injection.

47 (previously presented). The method of claim 37, wherein said receptor activity affecting compound is administered to the patient via injection.